Results 51 to 60 of about 1,763 (188)

Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer. [PDF]

open access: yes, 2019
In metastatic castration-refractory prostate cancer (mCRPC), state-of-the-art treatment consists of androgen biosynthesis inhibition (abiraterone), inhibition of the androgen receptor (enzalutamide), chemotherapy, or radium-223 in combination with ...
Everaerts, Wouter   +17 more
core   +1 more source

Ablative radiotherapy in castration‐resistant prostate cancer

open access: yesBJU International, Volume 138, Issue 4, Page 659-665, October 2026.
Objective To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration‐resistant prostate cancer (CRPC) a single‐centre randomised trial was initiated. Patients and Methods This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate‐specific membrane antigen ...
Tobias Hölscher   +9 more
wiley   +1 more source

Outcomes of Radiotherapy in Oligoprogressive Breast Cancer

open access: yesJournal of Personalized Medicine
Introduction: Radiotherapy (RT) shows potential for improving local control in cases of oligoprogressive metastatic breast cancer (mBC). This retrospective analysis aims to evaluate the advantages of RT in such a clinical scenario. Methods: We conducted a retrospective analysis including patients with mBC who received radiation therapy (RT) for up to ...
Fabio Marazzi   +21 more
openaire   +3 more sources

Rechallenge With Immunotherapy for ES‐SCLC: Efficacy and Safety From a Retrospective Propensity Score‐Matched Study

open access: yesCancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Although immunotherapy combined with platinum‐based chemotherapy is now the standard first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC), the benefit of continuing immune checkpoint inhibitors (ICIs) after disease progression (PD) remains uncertain.
Yuxia Wang   +4 more
wiley   +1 more source

Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation

open access: yes, 2022
Objective: To study whether delivering definitive radiotherapy (RT) to sites of oligoprogression in metastatic renal cell carcinoma (mRCC) enabled deferral of systemic therapy (ST) changes without compromising disease control or survival.
Tang, Chad   +35 more
core   +1 more source

Traitement des oligometastases et oligoprogression

open access: yesCancer/Radiothérapie, 2019
Resume Nous proposons dans cette revue de rapporter l’impact de la radiotherapie stereotaxique chez les patients ayant un cancer oligometastatique ou en oligoprogression en termes de survie sans progression metastatique et globale, et d’identifier quelle est la place de cette modalite de radiotherapie au sein du parcours–patient.
Bourgier, C.   +9 more
openaire   +2 more sources

Remarkable Response to Immune Checkpoint Inhibition After Early Aggressive Recurrence Following Robot‐Assisted Radical Cystectomy for Bladder Squamous Cell Carcinoma: A Case Report

open access: yesIJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Squamous cell carcinoma is a rare bladder cancer subtype with poor prognosis in advanced stages. Currently, there is no established systemic therapy, including immune checkpoint inhibitors, for this subtype. Case Presentation A 49‐year‐old man with pure bladder squamous cell carcinoma arising from a diverticulum with pelvic lymph ...
Kazuma Soya   +7 more
wiley   +1 more source

Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer

open access: yesThe Cancer Journal, 2020
Abstract Our understanding of metastatic disease is rapidly advancing, with recent evidence supporting an oligometastatic state currently defined by patients having a limited (typically ≤5) number of metastatic deposits. The optimal management of these patients is also shifting toward increased integration of local therapies, with emerging ...
Matthew P, Deek, Phuoc T, Tran
openaire   +3 more sources

Radioiodine‐Refractory Differentiated Thyroid Cancer: Definition, Molecular Mechanisms, and Advances in Precision Therapy

open access: yesCancer Innovation, Volume 5, Issue 4, August 2026.
Radioiodine‐refractory differentiated thyroid cancer (RAIR‐DTC) management now spans selective kinase inhibitors, MAPK‐pathway redifferentiation, VEGFR multikinase TKIs, and biomarker‐driven immunotherapy. We propose a three‐axis decision framework integrating molecular driver, evidence level, and patient dimension to guide individualized treatment ...
Yamin Li, Zuoxiang He
wiley   +1 more source

Hypofractionated Image-Guided Radiation Therapy With Simultaneous-Integrated Boost Technique for Limited Metastases: A Multi-Institutional Analysis

open access: yesFrontiers in Oncology, 2019
Purpose: To perform a multi-institutional analysis following treatment of limited osseous and/or nodal metastases in patients using a novel hypofractionated image-guided radiotherapy with simultaneous-integrated boost (HIGRT-SIB) technique.Methods ...
Corbin D. Jacobs   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy